AEM vs HMY

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

HMY exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptional ROE of 33.49%. The stock is significantly undervalued relative to its intrinsic value of $46.02 and trades at a remarkably low PEG ratio of 0.03. While the company faces short-term liquidity concerns (Current Ratio 0.54) and a poor earnings surprise track record, the combination of low debt and strong growth metrics suggests a deep-value opportunity.